Biotech | January 18, 2022
DCGI approves Phase 3 clinical trial of Stempeucel to treat Covid-19 patients
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
The drug is aimed at treating Covid-19 patients with Acute Respiratory Distress Syndrome (ARDS)
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
Dr Woler joins Sygnature Discovery after the company received significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co, in 2021
The company has 47 ANDA's pending approval with the U.S.FDA
The global multi-center phase-II clinical trial will be a 36-week, multi-center, randomized, double-blind, placebo-controlled trial, followed by a 36-week open-label extension period
Narayanan to lead SeQuent through next phase of consolidation and growth
The company has 271 cumulative ANDA filings with USFDA of which 243 ANDAs have been approved and 28 are pending approval
The new collaboration focuses on a class of proteins called transcription factors, which control gene expression and can regulate important cellular processes including cell growth and survival
Their strong recommendation is based on moderate certainty evidence that it improves survival and reduces the need for ventilation
Subscribe To Our Newsletter & Stay Updated
